Ex vivo drug testing in patient-derived papillary renal cancer cells reveals EGFR and the BCL2 family as therapeutic targets
Loading...
Author (Corporation)
Publication date
2023
Typ of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
European Urology Focus
Special issue
DOI of the original publication
Link
Series
Series number
Volume
Issue / Number
Pages / Duration
Patent number
Publisher / Publishing institution
Elsevier
Place of publication / Event location
Edition
Version
Programming language
Assignee
Practice partner / Client
Keywords
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
2405-4569
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Publication status
Published
Review
Peer review of the complete publication
Open access category
Hybrid
License
Citation
Angori, S., Banaei-Esfahani, A., Mühlbauer, K., Bolck, H. A., Kahraman, A., Karakulak, T., Poyet, C., Feodoroff, M., Potdar, S., Kallioniemi, O., Pietiäinen, V., Schraml, P., & Moch, H. (2023). Ex vivo drug testing in patient-derived papillary renal cancer cells reveals EGFR and the BCL2 family as therapeutic targets. European Urology Focus. https://doi.org/10.1016/j.euf.2023.03.005